Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  RTI Surgical Inc    RTIX

RTI SURGICAL INC (RTIX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

RTI BIOLOGICS INC : RTI Biologics, Medtronic Continue Strong Relationship

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/17/2010 | 04:25pm EST

RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading processor of orthopedic and other biologic implants, in response to inquiries regarding Medtronic's announced acquisition of Osteotech stated today that the relationship between Medtronic and RTI Biologics continues to be strong, with no changes near-term.

?We have received confirmation from Medtronic that our relationship is business as usual and they remain supportive of our current agreement, which runs through June 2014,? said Brian K. Hutchison, RTI chairman and CEO. ?Both companies have taken several steps over the years to continuously improve our relationship, and we have been assured that Medtronic will continue down that path with RTI. At this time we expect to continue to meet Medtronic's spinal allograft needs with high-quality, BioCleanse®-sterilized biologic implants.?

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI's innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI's worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's Web site at www.rtix.com or the SEC's Web site at www.sec.gov.

RTI Biologics Inc., Alachua
Robert Jordheim, Chief Financial Officer
rjordheim@rtix.com
or
Wendy Crites Wacker, APR, Corporate Communications, 386-418-8888
wwacker@rtix.com


© Business Wire 2010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RTI SURGICAL INC
2018RTI Donor Services and Versiti Celebrate the Gift of Tissue Donation with Don..
GL
2018RTI SURGICAL : reg; Announces HealthPartners'® Positive Coverage Decision for Mi..
BU
2018NEW RESEARCH : Key Drivers of Growth for WellCare Health Plans, Streamline Healt..
AQ
2018RTI SURGICAL, INC. : Entry into a Material Definitive Agreement, Financial State..
AQ
2018RTI SURGICAL : Management's Discussion and Analysis of Financial Condition and R..
AQ
2018RTI SURGICAL, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2018RTI SURGICAL : reg; to Acquire Paradigm Spine
BU
2018RTI SURGICAL, INC. : Results of Operations and Financial Condition, Financial St..
AQ
2018RTI SURGICAL : 3Q Earnings Snapshot
AQ
2018RTI SURGICAL : reg; Announces Third Quarter 2018 Results
BU
More news
Financials ($)
Sales 2018 280 M
EBIT 2018 -
Net income 2018 -1,13 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0,97x
Capi. / Sales 2019 0,95x
Capitalization 272 M
Chart RTI SURGICAL INC
Duration : Period :
RTI Surgical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RTI SURGICAL INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 7,50 $
Spread / Average Target 75%
EPS Revisions
Managers
NameTitle
Camille I. Farhat President, Chief Executive Officer & Director
Curtis M. Selquist Chairman
John N. Varela Executive Vice President-Global Operations
Jonathon M. Singer CFO, Secretary & Chief Administrative Officer
Lennox K. Archibald Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
RTI SURGICAL INC15.68%272
STRYKER CORPORATION5.82%62 070
SMITH & NEPHEW-1.37%16 301
WRIGHT MEDICAL GROUP NV5.07%3 577
GLAUKOS CORP9.24%2 211
DOUBLE MEDICAL TECHNOLOGY INC--.--%1 768